Inovio says covid-19 vaccine candidate to enter phase 2/3 study in sept - conf call

Inovio pharmaceuticals says covid-19 vaccine candidate to enter phase 2/3 study in september - conf call.inovio says in process of finalizing additional manufacturing partnerships in the u.s. and europe to fulfill vaccine candidate production goal of 1 million doses in 2020 and 100 million by 2021 - conf call.inovio says expect data updates from china, south korea covid-19 vaccine studies in q4 - conf call.inovio plans to make announcements about expanding vaccine manufacturing consortium in the next few months - conf call.inovio says aims to secure additional external funding to scale up manufacturing of vaccine candidate for covid-19 - conf call.inovio says phase 2/3 covid-19 vaccine trial will be in the same order of maginitude as nih's master protocol - conf call.inovio says don't think will be practically limited by the number of volunteers for phase 3 covid-19 vaccine trial - conf call.inovio says following up with patients from phase 1 covid-19 vaccine trial 13 months after final dose, to see durability of immune response - conf call.inovio says its vaccine candidate can be kept at room temperature for over a year and in normal refrigeration for up to 5 years - conf call.inovio says exploring partnerships beyond u.s. and europe for manufacturing partnerships for vaccine candidate - conf call.inovio expects its covid-19 vaccine will be priced similar to those announced by other companies - conf call.
INO Ratings Summary
INO Quant Ranking